# Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Source: https://onco.cc/trials/nct02480374/  
OnCo record `nct02480374` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of IMNN-001 run by Imunon, completed.

## Summary

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer is a phase 1 interventional study registered as NCT02480374 by Imunon, with 18 participants enrolled, started 2015-09. Conditions recorded: Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer. Interventions recorded: IMNN-001.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02480374
- Phase: 1
- Setting: A Phase I Study of the Safety and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Sponsor: Imunon
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT02480374: https://clinicaltrials.gov/study/NCT02480374

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [IMNN-001](https://onco.cc/drugs/imnn-001/)
- companies: [Imunon](https://onco.cc/companies/imunon/)

---
JSON: https://onco.cc/api/v1/entities/nct02480374.json